• Policy
• Overseas direct purchases of GLP-1 obesity drugs banned
• by Lee, Hye-Kyung Oct 23, 2024 05:50am

• Policy
• New drug expenditure is 13.5% of NHI finance's drug spending
• by Whang, byung-woo Oct 23, 2024 05:49am

• Policy
• Dongkook receives reimb for s-amlodipine triple-drug combo
• by Lee, Tak-Sun Oct 22, 2024 05:52am

• Policy
• MFDS grants EUA to COVID-19 variant vaccine for infants
• by Lee, Hye-Kyung Oct 22, 2024 05:51am

• Policy
• 2nd GIFT drug Nefecon’s approval imminent in Korea
• by Lee, Hye-Kyung Oct 21, 2024 05:48am

• Policy
• How to stabilize supply of national essential medicines
• by Lee, Hye-Kyung Oct 18, 2024 05:49am

• Policy
• 'Can the Yoon administration develop blockbuster drugs?'
• by Lee, Jeong-Hwan Oct 18, 2024 05:49am

• Policy
• Gov't opposes to suspending reimb·ingredient prescribing
• by Lee, Jeong-Hwan Oct 17, 2024 05:52am

• Policy
• HIRA President, "Copayment ratio needs to be adjusted
• by Lee, Tak-Sun Oct 17, 2024 05:51am

• Policy
• Alvogen receives approval for its Humira biosimilar in KOR
• by Lee, Hye-Kyung Oct 17, 2024 05:51am